Limits...
Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009

View Article: PubMed Central - HTML

ABSTRACT

Overall prevalence of samples showing evidence of any PI resistance decreased gradually over time (from 2003 to 2009: 47.0% to 32.2% [VTY lower CCO]; 49.1% to 42.2% [US-FDA mutation list]. Mean prevalence of each of the 11 individual DRV RAMs also decreased over time (Figure 1)

Prevalence of samples harbouring ≥1 DRV RAMs also decreased over time. In 2009, 94.3% of all samples harboured zero DRV RAMs versus 85.3% in 2003. Among samples with evidence of PI resistance, 88% vs 72% (per FDA list) and 84% vs 70% (to any PI defined by predicted FC> low CCO) harboured zero DRV RAMs. The most common three DRV RAM combination was L33F,I54L,I84V which was detected with a prevalence of 0.15% in 2003 and 0.08% in 2009.

No MeSH data available.


2009 IAS-USA DRV RAMs as a proportion of samples with evidence of PI resistance by VTY lower CCO.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3112908&req=5

Figure 1: 2009 IAS-USA DRV RAMs as a proportion of samples with evidence of PI resistance by VTY lower CCO.

Mentions: Overall prevalence of samples showing evidence of any PI resistance decreased gradually over time (from 2003 to 2009: 47.0% to 32.2% [VTY lower CCO]; 49.1% to 42.2% [US-FDA mutation list]. Mean prevalence of each of the 11 individual DRV RAMs also decreased over time (Figure 1)


Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009
2009 IAS-USA DRV RAMs as a proportion of samples with evidence of PI resistance by VTY lower CCO.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3112908&req=5

Figure 1: 2009 IAS-USA DRV RAMs as a proportion of samples with evidence of PI resistance by VTY lower CCO.
Mentions: Overall prevalence of samples showing evidence of any PI resistance decreased gradually over time (from 2003 to 2009: 47.0% to 32.2% [VTY lower CCO]; 49.1% to 42.2% [US-FDA mutation list]. Mean prevalence of each of the 11 individual DRV RAMs also decreased over time (Figure 1)

View Article: PubMed Central - HTML

ABSTRACT

Overall prevalence of samples showing evidence of any PI resistance decreased gradually over time (from 2003 to 2009: 47.0% to 32.2% [VTY lower CCO]; 49.1% to 42.2% [US-FDA mutation list]. Mean prevalence of each of the 11 individual DRV RAMs also decreased over time (Figure 1)

Prevalence of samples harbouring ≥1 DRV RAMs also decreased over time. In 2009, 94.3% of all samples harboured zero DRV RAMs versus 85.3% in 2003. Among samples with evidence of PI resistance, 88% vs 72% (per FDA list) and 84% vs 70% (to any PI defined by predicted FC> low CCO) harboured zero DRV RAMs. The most common three DRV RAM combination was L33F,I54L,I84V which was detected with a prevalence of 0.15% in 2003 and 0.08% in 2009.

No MeSH data available.